Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib in KIF5B-RET-Positive Lung Adenocarcinoma
NCT01877083Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2013
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in lung adenocarcinoma, sponsored by Eisai Co., Ltd. Primary endpoint: Objective Response Rate. Started Apr 2013; status: completed.
02
Drugs
lenvatinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT01877083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01877083.